Avelis Biotech Raises $250K in Initial Funding

Avelis Biotech has announced that it has raised an initial $250,000 in capital from a private investor. Avelis is an Illinois-based biotechnology company with operations in Illinois, Louisiana and Arizona. Avelis is a green biotechnology company focused on creating intellectual property that optimizes nutrient lifecycles, solves chemical-related problems, and reduces the cost of fossil fuel to businesses. Avelis technologies are increasingly ready for the market and provide organic formulations that are real solutions to global food and water crises, for which no synthetic or organic product is currently in use. The company is already delivering the product to early customers

“This capital increase represents a significant step in our strategic plan and will provide the capital needed to continue the expansion of our intellectual property portfolio and to commercialize technology in key growth markets,” said Dr. Justin Cannock, Chairman and Chief Scientific Officer of Avelis Biotech “We appreciate the confidence of our investors in Avelis’ ability to create long-term shareholder value as we enhance our customer offerings and gain market share. “That’s right.

The new capital will expand and diversify the Avelis investor base, further strengthen its balance sheet, enable the Company to leverage its investment in R&D and intellectual property protection over the last five years, and support the expansion of its subsidiary in key markets around the globe.

Avelis has identified three vertical markets for the immediate distribution of its products on the basis of patented proprietary technologies pending: soil remediation; water remediation; livestock feed economizer. Technologies are based on discoveries using non-synthesized chemistry that optimize cell molecular mechanisms.

These technologies play a central role in providing unique, cost-effective and sustainable solutions for soil and water remediation and in reducing dependence on petrochemicals in agriculture. The company’s mature R&D portfolio includes laboratory and field trials, third party university and government validation, sourcing and scalability.

The company operates at the SkySong Global Innovation Center in Scottsdale, Arizona, and is supported by the ASU Venture Catalyst.

Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Avelis%20Biotech/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co